Atypicality of Several Antipsychotics on the Basis of in Vivo Dopamine

Total Page:16

File Type:pdf, Size:1020Kb

Atypicality of Several Antipsychotics on the Basis of in Vivo Dopamine ELSEVIER Atypicality of Several Antipsychotics on the Basis of In Vivo Dopamine-D2 and Serotonin-SHT2 Receptor Occupancy Tomiki Sumiyoshi, M.D., Kimiko Suzuki, M.D., Hiroshi Sakamoto, M.D., Nariyoshi Yamaguchi, M.D., Hirofumi Mori, M.D., Kazuhiro Shiba, Ph.D., and Koichi Yokogawa, Ph.D. An in vivo receptor binding technique was used to were found for clozapine, RMI-81512, and tiospirone evaluate the binding profiles of typical and atypical compared to haloperiodol and pimozide. Zotepine, antipsychotic drugs to striatal dopamine-D2 and frontal mosapramine, and clocapramine produced ratios that fall serotonin-S-HT2 receptors in a rat brain using more between these two groups. Chlorpromazine was specific ligands than those previously employed. [3HJ­ exceptional as a typical antispychotic by these criteria. YM-09151-2 or {3H]-ketanserin was injected into the tail Relatively strong antagonism of S-HT2 receptors by vein 10 minutes after administration of test drugs. One atypical antipsychotics was confirmed by this in vivo hour after the ligand injection, radioactivities in the measure of receptor binding using more selective ligands striatum, frontal cortex, and cerebellum were counted to than those used in previous studies. obtain receptor occupancies by the test drugs. Higher [Neuropsychopharmacology 12:57-64, 1995] ratios of potency in occupying 5-HT2 versus D2 receptors KEY WORDS: Atypical antipsychotic drugs; D2 receptors; likely to produce disturbances of EPS or elevation of S-HT2 receptors; Receptor binding study; In vivo serum prolactin (Young and Meltzer 1980; Porsolt and Jafre 1981; Neale et al. 1983), and demonstrate favor­ positive and negative The mode of action of antipsychotic drugs has been dis­ able clinical efficacy for both are resistant to treatment cussed in relation to their potency to block central symptoms of patients who et al. 1988). dopamine-D2 receptors (Creese et al. 1976; Seeman et with typical antipsychotics (Kane for serotoninz (5-HT2) al. 1976). The so-called "typical" antipsychotic drugs Since a relatively high affinity drugs was postulated have been shown to produce catalepsy in rats (Moore receptors of atypical antipsychotic Meltzer et al. (1989a, b), a number of studies to test and Gershon 1989) and often, extrapyramidal side by in laboratory effects (EPS) in patients (Sovner and DiMascio 1978), this hypothesis have been performed et al. 1992; Stock­ by blocking the nigrostriatal dopamine system. "Atyp­ animals (Leysen et al. 1992; Matsubara PET measurement ical" antipsychotic drugs, on the other hand, are less meier et al. 1993) and in human (Nordstrom et al. 1993; Nyberg et al. 1993). We have previously demonstrated that the atypical antipsychotic From the Department of Neuropsychiatry (TS, KS, HS, NY) Ra­ drugs clozapine, RMI-81582, and risperidone show rel­ dioisotope Center (HM, KS) and Hospitals Pharmacy (KY) of Kanazawa, University School of Medicine, Kanazawa 920, Japan atively higher 5-HT2 to D2 ratios of in vivo receptor Address correspondence to: Tomiki Sumiyoshi, M.D., Department affinities than haloperidol, measuring time courses of of Psychiatry, University Hospitals of Cleveland, Hanna Pavilion, a receptor occupancy by single doses of these drugs 11100 Euclid Ave, Cleveland, OH 44106. Received February 16, 1994; revised July 8, 1994; accepted July 19, (Sumiyoshi et al. 1993, 1994a, b). 1994. In the present study, we used [3H]-YM-09151-2 and NEUROPSYCHOPHARMACOLOGY 1995-VOL. 12, NO. 1 © 1995 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 0893-133X/95/$9 .50 655 Avenue of the Americas, New York, NY 10010 SSDI 0893-133X(94)00064-7 58 T. Sumiyoshi et al. NEUROPSYCHOPHARMACOLOGY 1995-VOL. 12, NO. 1 [3H]-ketaserin, selective ligands for D2 and 5-HT2 re­ Xno)/(Xs-Xns] x 100 (%), where each abbreviation ceptors, respectively (Laduron et al. 1982; Niznik et al. represents the radioactivity (%dose/g tissue) of Xo, 1985; Terai et al. 1989), to measure the in vivo affinities striatum, or frontal cortex of drug-treated rats; Xno, of several antipsychotic drugs to these receptors by cerebellum of drug-treated rats; Xs, striatum or fron­ analyzing receptor occupancy. The test compounds in­ tal cortex of vehicle-treated rats; and Xns, cerebellum clude the new antipsychotic drug Y-516 (mosapramine) of vehicle-treated rats. andclocapramine,iminodibenzylderivativesthathave been shown to exert favorable clinical effect on schizo­ Data Analysis phrenic patients (Yamagami et al. 1988; Asano et al. 1992). The "atypicality" of these iminodibenzyls is also Dose-response competition curves were analyzed with determined on the basis of in vivo D2 and 5-HT2 recep­ the minimal-square method (Paalzow and Edlund 1979) tor occupancy in comparison with traditional typical and DEso (mg/kg) values reflecting binding potencies and atypical antipsychotics. of the test drugs were calculated. The EDso values were then transformed into (-)log of the EDso (mol/kg) (pEDso) to compare the receptor binding potencies of MATERIALS AND METHODS the test drugs in the present study with those of Stock­ meier et al. (1993). In Vivo Receptor Binding Male Wistar rats (210 to 240 g; Sankyo Laboratory, Drugs Toyama, Japan) were housed in a temperature-con­ trolled room with a 12-hour dark/light cycle (lights on [3H]-YM-09151-2 (specific activity 3.22 TBq/mmol) and at 8:30) and had free access to food and water. In vivo [3H]-ketanserin (specific activity 2.22 TBq/mmol) were binding of [3H]-YM-09151-2 (specific activity 3.22 purchased from DuPont New England Nuclear Corpo­ TBq/mmol) to D2 receptors or [3H]-ketanserin (specific ration (Boston, MA). The following compounds were activity 2.22 TBq/mmol) to 5-HT2 receptors was mea­ generously supplied by the manufacturers: haloperidol sured according to a method previously reported (DainipponPharmaceutical Co., Osaka, Japan); cloza­ (Sumiyoshi et al. 1993, 1994a, b). For the kinetic study, pine (Sandoz Ltd., Basel, Switzerland); RMI-81582 [3H]-YM-09151-2 or [3H]-ketanserin (1540 to 1680 kBq/ (Marion Merrill Dow Pharmaceuticals, Cincinnati, OH); kg body weight) were injected into the lateral tail vein tiospirone (Bristol-Myers-Squibb, Wallingford, CT); of rats that had received an intraperitoneal injection of chlorpromazine, mosapramine, clocapramine (Yoshi­ a vehicle (dimethyl-sulfoxide, Wako Chemical Co., tomi Pharmaceutical Ltd., Osaka, Japan); zotepine, Oaska, Japan, 1 ml/kg), 10 minutes before. The rats were pimozide (Fujisawa Pharmaceutical Co., Osaka, Japan). sacrificed by decapitation at 15, 30, 45, 60, 120, or 240 minutes after the injections of ligands. For competition RESULTS studies, rats were pretreated with an intraperitoneal in­ jection of varying doses of antipsychotic drugs or the The values of radioactivity in each brain region at the same volume (0.21 to O.24 ml) of the corresponding ve­ different time intervals after the injection of [3H]-YM- hicle (dimethyl-sulfoxide), 10 minutes prior to the in­ 09151-2 are shown in Figure 1. A relatively large amount jection of [3H]-YM-09151-2 or [3H]-ketanserin. Based of [·3H]-YM-09151-2 accumulates in the striatum as on results of the kinetic study, the rats were decapi­ compared to the cerebellum. For [3H]-ketanserin­ tated 60 minutes after the ligand injection. The brains treated rats, the values in the frontal cortex continued were rapidly removed and dissected into cerebellum, to be higher than those in the cerebellum, as shown striatum, frontal cortex, and the rest of the brain. After in Figure 2. In the following drug competition studies, weighing, each region of the brain was solubilized with rats were sacrificed 60 minutes after the injection of a tissue solubilizer (Soluene 350, Packard Co., CN) by radioligand, based on stable receptor occupancies by incubation for 2 to 3 hours at 50°C. A scintillation cock­ drugs at this time point as reported in our previous tail (Aquasol 2, New England Nuclear) was added to studies (Sumiyoshi et al. 1993, 1994a, b). Figures 3 to the solubilized tissues adjusted to pH 7.0 with 0.5 N 10 show the occupancy of 04 and 5-HT2 receptors fol­ HO solution (for inhibition of pseudo-fluorescence). Af­ lowing various doses of typical antipsychotic drugs, ter 12 to 24 hours, the radioactivity concentrations in pimozide and chlorpromazine; atypical antipsychotic the tissues were counted with a liquid scintillation drugs, clozapine, RMI-81582 and tiospirone; other counter (LSC-1000, Aloka Co., Tokyo, Japan) and the drugs, zotepine, mosapramine and clocapramine. The values, expressed as o/odose/g tissue, were calculated. dose-occupancy curves of haloperidol were reported Receptor occupancy was determined by a modification elsewhere (Sumiyoshi et al. 1994a). Based on these oc­ of the method of former reports (Geoders and Kuhar cupancy curves, the EDso values (mg/kg) of the test 1985; Miller et al. 1987): percent occupancy <1>=[1-(Xo- compounds for the in vivo occupancy of striatal D2 and NEUROPSYCHOPHARMACOLOGY 1995-VOL. 12, NO. 1 In Vivo Receptor Occupancy of Antipsychotics 59 .......... (I) ::J (/) (/) 2.0 i 100 -~ e 'OD (I) ..........• 1.5 a Striatum >, -(/) 0 0 0 . .t.. Cerebellum -0 (/) 50 a. 1.0 ::, o*+I C 0 .._.. ro 0 >, (I) 0 ·"'= >-E 0.5 Jl -~ -ii (.) ro 0.1 0 -0 0 0 ro 30 60 120 240 Dose of Pimozide (mg/kg) 0:: Time (minutes) Figure 3. Occupancy (<I>%) of striatal D2 and frontal 5-HT2 receptors in rat brain with various doses of pimozide. [3H]­ Figure 1. Kinetics of [3H]-YM-09151-2 binding in vivo in rat YM-09151-2 or [3H]-ketanserin (1540 to 1680 kBq/kg body brain. Rats were injected with [3H]-YM-09151-2 (1540 to 1680 weight) was injected into a tail vein at 10 minutes after ad­ kBq/kg body weight) at time zero and killed at various times ministration (IP) with various doses of pimozide. Sixty after injection. Values represent the mean± SD of five rats minutes after the ligand injection, radioactivity in the stria­ at each time point.
Recommended publications
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green Et Al
    US009381189B2 (12) United States Patent (10) Patent No.: US 9,381,189 B2 Green et al. (45) Date of Patent: Jul. 5, 2016 (54) INGREDIENTS FOR INHALATION AND (56) References Cited METHODS FOR MAKING THE SAME U.S. PATENT DOCUMENTS (75) Inventors: Matthew Michael James Green, 4,582,265 A * 4/1986 Petronelli ....................... 241.95 Wiltshire (GB); Richard Michael Poole, 6,257,233 B1 7/2001 Burr et al. 2004/01 18007 A1* 6/2004 Chickering et al. ............ 34/360 Wiltshire (GB) 2006, O257491 A1* 11, 2006 Morton et al. ... 424/489 (73) Assignee: VECTURA LIMITED, Wiltshire (GB) 2008/0063719 A1 3/2008 Morton et al. ................ 424/489 (*) Notice: Subject to any disclaimer, the term of this FOREIGN PATENT DOCUMENTS patent is extended or adjusted under 35 EP O709086 A2 5, 1996 U.S.C. 154(b) by 641 days. EP 14981 16 A1 1, 2005 GB 2387781 A 10, 2003 JP 2005298.347 10/2005 (21) Appl. No.: 13/514,672 JP 200954.1393 11, 2009 JP 2012,542618 6, 2012 (22) PCT Fled: Dec. 8, 2010 WO 96.23485 A1 8, 1996 WO 9703649 A1 2, 1997 (86) PCT NO.: PCT/GB2O10/052053 WO O2OO197 A1 1, 2002 WO O243701 A2 6, 2002 S371 (c)(1), WO 2005105043 A2 11/2005 Aug. 20, 2012 WO 2007053904 A1 5/2007 (2), (4) Date: WO 2008.000482 1, 2008 (87) PCT Pub. No.: WO2O11AO70361 WO 2009095684 A1 8, 2009 OTHER PUBLICATIONS PCT Pub. Date: Jun. 16, 2011 Brunauer et al. "Adsorption of Gases in Multimolecular Layers'. J. (65) Prior Publication Data Am.
    [Show full text]
  • Centre for Reviews and Dissemination
    Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta- analysis Leucht S, Corves C, D Arbter, Engel R R, Li C, Davis J M CRD summary The authors concluded that amisulpride, clozapine, olanzapine and risperidone can be effective in treating schizophrenia patients. Second-generation antipsychotic drugs can also result in fewer extrapyramidal side effects, but can induce weight gain. The authors' conclusions reflected the evidence presented, but some potential methodological flaws in the review process meant that the extent to which those conclusions were reliable was unclear. Authors' objectives To compare the effects of first and second-generation antipsychotic drugs in schizophrenia patients. Searching The search for eligible studies was started in 2005, including MEDLINE to October 2006, Cochrane Schizophrenia Group's Specialised Register and the US Food and Drugs Administration website. Search terms were reported and there were no language restrictions. Previous reviews were searched for additional relevant studies. Study selection Randomised controlled trials (RCTs) of oral second-generation antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine) compared with first-generation drugs in patients with schizophrenia or related disorders (schizoaffective, schizophreniform or delusional disorders) irrespective of diagnostic criteria were eligible for inclusion in the review. The optimum doses of second-generation drugs were selected
    [Show full text]
  • Haloperidol Versus Placebo for Schizophrenia
    Haloperidol versus placebo for schizophrenia Item Type Article Authors Irving, Claire B.; Adams, Clive E. Citation Irving, C. B., Adams, C. E. & Lawrie, S. (2006). Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, (4), pp.1-69. Download date 25/09/2021 21:20:50 Link to Item http://hdl.handle.net/20.500.12904/9860 Haloperidol versus placebo for schizophrenia (Review) Irving CB, Adams CE, Lawrie S This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2006, Issue 4 http://www.thecochranelibrary.com Haloperidol versus placebo for schizophrenia (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 6 DISCUSSION ..................................... 10 AUTHORS’CONCLUSIONS . 11 ACKNOWLEDGEMENTS . 11 REFERENCES ..................................... 12 CHARACTERISTICSOFSTUDIES . 25 DATAANDANALYSES. 67 Haloperidol versus placebo for schizophrenia (Review) i Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Review] Haloperidol versus placebo for schizophrenia Claire B Irving1, Clive E Adams1, Stephen Lawrie2 1Cochrane Schizophrenia
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0179214 A1 Dubé Et Al
    US 20100179214A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0179214 A1 Dubé et al. (43) Pub. Date: Jul. 15, 2010 (54) DOXEPIN TRANS ISOMERS AND SOMERC continuation-in-part of application No. 1 1/804,720, MIXTURES AND METHODS OF USING THE filed on May 18, 2007. SAME TO TREAT SLEEP DSORDERS (60) Provisional application No. 60/898,378, filed on Jan. (75) Inventors: Susan E. Dubé, Carlsbad, CA (US); 30, 2007, provisional application No. 60/801,824, Neil B. Kavey, Chappaqua, NY filed on May 19, 2006, provisional application No. (US) 60/833,319, filed on Jul 25, 2006. Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP Publication Classification 2040 MAINSTREET, FOURTEENTH FLOOR (51) Int. Cl. IRVINE, CA 92.614 (US) A63L/335 (2006.01) A6IP 25/20 (2006.01) (73) Assignee: SOMAXON PHARMACEUTICALS, INC., (52) U.S. Cl. ........................................................ S14/450 San Diego, CA (US) (21) Appl. No.: 12/535,623 (57) ABSTRACT The invention relates to use of the trans-(E) isomer or iso (22) Filed: Aug. 4, 2009 meric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, phar Related U.S. Application Data maceutically-acceptable salts of doxepin and prodrugs of the (63) Continuation-in-part of application No. 12/022,788, same; compositions containing the same, for the treatment of filed on Jan. 30, 2008, now abandoned, which is a sleep disorders US 2010/0179214 A1 Jul. 15, 2010 DOXEPIN TRANS ISOMERS AND SOMERC brings scrutiny from the Drug Enforcement Administration MIXTURES AND METHODS OF USING THE and other regulatory bodies, and requires registration and SAME TO TREAT SLEEP DSORDERS administrative controls in physicians offices.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al
    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Maternal Use of Psychiatric Medications During Pregnancy And
    MATERNAL USE OF PSYCHIATRIC MEDICATIONS DURING PREGNANCY AND ADVERSE BIRTH OUTCOMES AND NEURODEVELOPMENTAL PROBLEMS IN OFFSPRING Ayesha C. Sujan Submitted to the faculty of the University Graduate School in partial fulfillment of the requirements for the degree Doctor of Philosophy in the Department of Psychological and Brain Sciences, Indiana University July 2021 ii Accepted by the Graduate Faculty, Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Doctoral Committee _______________________________________________ Brian M. D’Onofrio, PhD _______________________________________________ Richard Viken, PhD _______________________________________________ Patrick D. Quinn, PhD _______________________________________________ Christina Ludema, PhD _______________________________________________ A. Sara Oberg, PhD, MD April 22nd, 2020 iii © 2021 Ayesha C. Sujan iv Ayesha Sujan MATERNAL USE OF PSYCHIATRIC MEDICATIONS DURING PREGNANCY AND ADVERSE BIRTH OUTCOMES AND NEURODEVELOPMENTAL PROBLEMS IN OFFSPRING Understanding consequences of prenatal exposure to psychiatric and analgesic medications is important because use of these medications among pregnant women is relatively common and increasing. Rodent experiments have shown effects of perinatal exposure to specific medications; however, these findings might not apply to humans. Human observational studies have been used to study prenatal exposure to psychiatric and analgesic medications rather than randomiZed control trials due to ethical concerns
    [Show full text]
  • Revision of Precautions Asenapine Maleate, Aripiprazole, Olanzapine
    Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. Revision of Precautions Asenapine maleate, aripiprazole, olanzapine, quetiapine fumarate, clocapramine hydrochloride hydrate, chlorpromazine hydrochloride, chlorpromazine hydrochloride/promethazine hydrochloride/phenobarbital, chlorpromazine phenolphthalinate, spiperone, zotepine, timiperone, haloperidol, paliperidone, pipamperone hydrochloride, fluphenazine decanoate, fluphenazine maleate, brexpiprazole, prochlorperazine maleate, prochlorperazine mesilate, Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: [email protected] Published by Translated by Ministry of Health, Labour and Welfare Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. propericiazine, bromperidol, perphenazine, perphenazine hydrochloride, perphenazine fendizoate, perphenazine maleate, perospirone hydrochloride hydrate, mosapramine hydrochloride, risperidone (oral drug), levomepromazine hydrochloride, levomepromazine maleate March 27, 2018 Non-proprietary name Asenapine maleate,
    [Show full text]
  • List of Vital Essential and Necessary Drugs and Medical Sundries For
    LIST OF VITAL ESSENTIAL AND NECESSARY DRUGS AND 2015 MEDICAL SUNDRIES FOR PUBLIC HEALTH INSTITUTIONS Sixth Edition STANDARDS & REGULATION DIVISION JAMAICA List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions CONTENTS CONTENTS Contd. Page Preface 5-6 Page Information on Hospitals and Health Centres 7 Explanatory Notes 8 Medical Sundries 69-73 Prescription Writing 9-10 Dental Supplies 74 Algorithm for Treatment of Hypertension 11-12 Radiotherapy – Diagnostic Agents 75 Algorithm for Management of Type 2 Diabetes 13-14 Raw Materials 76 List of Drugs Designated for NHF 15-17 List of Drugs Designated for JADEP 18 VOLUME11 – SPECIALIST LIST 77 VOLUME 1 – GENERAL LIST 19 CLASSIFICATION OF DRUGS SECTION 1. Cardiovascular System 78 CLASSIFICATION OF DRUGS SECTION 2. Central Nervous System 79 SECTION 1. Cardiovascular System 20-24 SECTION 3. Dermatology 80 SECTION 2. Central Nervous System 25-30 SECTION 4. Endocrine System 80 SECTION 3. Dermatology 31-33 SECTION 5. Gastro-intestinal System 81 SECTION 4. Ear, Nose and Oropharynx 34-35 SECTION 6. Infections 81 SECTION 5. Endocrine System 36-38 SECTION 7. Malignant Disease and SECTION 6. Gastro-intestinal System 39-40 Immunosuppression 82 SECTION 7. Infections 41-46 SECTION 8. Musculoskeletal and Joint Diseases 83 SECTION 8. Malignant Disease and SECTION 9. Ophthalmology 83 Immunosuppression 47-49 SECTION 10. Genito-Urinary Tract Disorders 84 SECTION 9. Musculoskeletal and Joint Diseases 50-51 SECTION 11. Respiratory System 84 SECTION 10. Nutrition and Blood 52-54 SECTION 12.
    [Show full text]